Technical Analysis for MTNB - Matinas Biopharma Holdings, Inc.

Grade Last Price % Change Price Change
F 0.54 -4.42% -0.03
MTNB closed down 4.42 percent on Wednesday, November 20, 2024, on 28 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -4.42%
Narrow Range Bar Range Contraction -4.42%
Inside Day Range Contraction -4.42%
Wide Bands Range Expansion -4.42%

   Recent Intraday Alerts

Alert Time
Down 3% about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
Up 2% about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Matinas Biopharma Holdings, Inc. Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Pharmaceutical Drugs Inflammation Infection Antibiotics Bacterial Infections Antimicrobial Resistance Aminoglycoside Drug Resistance Multiple Drug Resistance

Is MTNB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.5
52 Week Low 0.5
Average Volume 248,449
200-Day Moving Average 7.66
50-Day Moving Average 2.58
20-Day Moving Average 1.19
10-Day Moving Average 0.66
Average True Range 0.25
RSI (14) 22.48
ADX 38.39
+DI 16.81
-DI 40.73
Chandelier Exit (Long, 3 ATRs) 3.16
Chandelier Exit (Short, 3 ATRs) 1.24
Upper Bollinger Bands 3.21
Lower Bollinger Band -0.83
Percent B (%b) 0.34
BandWidth 338.89
MACD Line -0.69
MACD Signal Line -0.73
MACD Histogram 0.0471
Fundamentals Value
Market Cap 117.32 Million
Num Shares 217 Million
EPS -0.10
Price-to-Earnings (P/E) Ratio -5.40
Price-to-Sales 21.78
Price-to-Book 1.97
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.60
Resistance 3 (R3) 0.60 0.59 0.59
Resistance 2 (R2) 0.59 0.58 0.59 0.59
Resistance 1 (R1) 0.57 0.57 0.56 0.56 0.58
Pivot Point 0.55 0.55 0.55 0.55 0.55
Support 1 (S1) 0.53 0.54 0.52 0.52 0.50
Support 2 (S2) 0.51 0.53 0.51 0.49
Support 3 (S3) 0.49 0.51 0.49
Support 4 (S4) 0.48